
April 23 (Reuters) - Xlife Sciences AG XLS.S:
FROM LAB TO UNICORN: XLIFE SCIENCES AG PORTFOLIO COMPANY VERAXA BIOTECH AG TO MERGE WITH VOYAGER ACQUISITION CORP. LISTED ON NASDAQ
XLIFE SCIENCES AG - TRANSACTION VALUES VERAXA BIOTECH AT USD 1.64 BILLION
XLIFE SCIENCES AG - VERAXA SHAREHOLDERS TO RECEIVE 130 MILLION SHARES
XLIFE SCIENCES AG - BUSINESS COMBINATION EXPECTED TO CLOSE IN Q4 2025
XLIFE SCIENCES AG - VERAXA TO BE LISTED ON NASDAQ UNDER TICKER SYMBOL VERX
XLIFE SCIENCES AG - VERAXA IS RAISING A CROSSOVER FINANCING ROUND FROM NEW AND EXISTING INVESTORS
XLIFE SCIENCES - PROCEEDS ARE EXPECTED TO PROVIDE CAPITAL FOR AT LEAST TWO YEARS AND SUPPORT PURSUIT OF KEY PARTNERSHIPS; CO-DEVELOPMENT OPPORTUNITIES